While GLP-1 drugs were originally designed for diabetes and obesity, clinical data show they significantly reduce markers of inflammation (like C-reactive protein, or CRP) remarkably quickly, usually long before any significant weight loss occurs
The analysis of 4887 participants treated with tirzepatide and 2,328 participants in the control groups identified 142 participants who developed at least one MACE-4p (inclusive of cardiovascular mortality, myocardial infarction, stroke, and hospitalization for unstable angina) and confirmed the cardiovascular safety with an hazard ratio (HR) of 0.80 (95% CI 0.571.11) for the comparison between tirzepatide and controls
The concentration you create when mixing your bacteriostatic water into the vial determines every syringe measurement for the life of that vial
Were Getting Closer to Edible GLP-1 Drugs Being Available Pharmaceutical companies are working on it That isnt the only company working on developing game-changing new drugs
In Alzheimers, the brain struggles to use this sugar properly